Feeds:
Posts
Comments

Archive for the ‘J&J’ Category

*****

TODAY’S NEWS

Big approval news for Gilead Sciences Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food and Drug Administration cleared sales of the medicine, given the brand name Cayston, the company said today in a statement. Outside advisers to the FDA backed the product’s safety and effectiveness in a 15-2 vote on Dec. 10more

What is the future of “personalized medicine”? Probably, it’ll look a lot like this (encouraging story from NY Times). Plus, in a cooperative effort, Eli Lilly, Merck and Pfizer have formed an independent, not-for-profit company Asian Cancer Research Group (ACRG) to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asiamore

Of course, in this industry, there is often a mix of good news and bad – and “bad” usually means bad behavior by people who love dollars above sense: lack of openness at AZ?; secret tapes and GSK (plus, a “fixer” who spiked research?); research fraud by rogue doc; kickbacks and J&J; risk of depression assessment and Eli Lilly (are you alive? then you’re at risk!!!). Reminds me of some prior posts on the Gold-in Rule

Novartis looking to expand even more at East Hanover campus. Including themed food venues!

RECOMMENDED

Marketing Training – Looking for resources for training brand marketing professionals? We know the providers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.

PLUS

I’m feeling much safer now. FDA finally comes out against “ear candling“! Next up, perhaps – a prohibition of USB-to-nasal-passage uploads??

JUST FOR FUN

Delightful (and BIG) pictures from Vancouver Olympics. Love the colors in the very first one. From Boston.com’s very nice The Big Picture section.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Review of this week’s snow-impacted ePharma Summit conference is now up on the blog!

TODAY’S NEWS

Benicar for kiddies – Olmesartan medoxomil (Benicar), approved in 2002 to treat high blood pressure in adults, has been sanctioned by the U.S. Food and Drug Administration to treat the same condition in children aged 6 to 16, drug maker Daiichi Sankyo said Thursdaymore

Ouch. More cuts at The Medicines Co. – Medicines Co said it would cut 43 jobs, or 26 percent of its field-based workforce, by the end of February, and take a related charge of $3.5 million in the first quartermore

Billy Tauzin leaving as head of PhRMA – The head of the influential trade association for drug manufacturers announced Thursday night that he is leaving his job. The development comes amid uncertainty over the fate of President Barack Obama’s health care overhaul, which the drug association had backed after striking a deal with the White House and Senate Democrats to limit costs to the industry in the legislationmore

J&J launches new social media initiatives.

RECOMMENDED

Social Media “listening” training and services – Getting started with a social media “listening” strategy? We can help by putting you in contact with the best providers. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Visual treat – Out-of-this-world coral photos. Yum.

JUST FOR FUN

31 Awesome benches. Oddly amusing!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Note: if you’re going to engage in questionable marketing practices, documenting it in Powerpoint is probably not a “best practice”! Just saying…

Experiment HIV drug from Merck fails in late-stage studies – Merck & Co  on Wednesday said its experimental HIV treatment vicriviroc proved ineffective in two late-stage studies involving patients who had previously been treated with other HIV medicines...more

Merck diarrhea drug does very well – Merck & Co.’s experimental drug against a germ blamed for increasing rates of deadly diarrhea in U.S. hospitals and nursing homes cut repeat infections by 72 percent, a study in the New England Journal of Medicine saidmore

Orphan drug applications are way up.

Upcoming oral MS drugs are very promising – Study results suggest they are much more effective than expensive “disease modifying” MS drugs such as beta interferon and glatiramer acetate, which have to be injected….more

Top biotech layoffs of 2009.

RECOMMENDED

Curriculum Analysis – We have partners that can analyze your current curriculum to insure it is tightly connected to key strategies and goals, identify gaps and build learning paths that support measurable results for key roles in your organization. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

E-detailing – Pfizer doubles its spending. I expect this trend to accelerate across the industry. It simply makes sense.

JUST FOR FUN

OCD Medication – instructions.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Pharma’s responses to the disaster in Haiti – good to see.

Novartis investing in “smart pills” – Novartis is ramping up its commitment to personalized medicine with a $24 million investment in Proteus Biomedical, a pioneer of high-tech pills featuring embedded ingestible sensors. Smart pills are a hot technology in the never-ending quest to improve drug delivery in novel, profitable ways…more

Rough week for J&J, with kickback accusations and recalled pills. John Mack over at Pharma Marketing Blog discusses whether J&J’s actions (social media communications and otherwise) were appropriate.

RECOMMENDED

Train-the-Trainer (facilitation skills, coaching skills, presentation skills, coaching, more). Amp-ing up the skills of your trainers? Need a specific program or an entirely re-designed curriculum? We have the proven partners you need in our vendor network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

JUST FOR FUN

Bizarre, funny, could be useful for chuckles during pharma sales training: check out the Zombie Rep series on YouTube!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

This will be the final Impactiviti Daily for 2009. We’ll pick up again in the new year. Have a delightful holiday season!

TODAY’S NEWS

Deals – J&J and Merck get hits, Biogen strikes out.

From PharmaExec – a new commercialization model needed for pharma? – The days when biopharmaceutical companies could rely upon a steady stream of blockbuster products to fuel sales and support large, fixed-cost infrastructures appear to be over. It is clear that with the issues facing the pharmaceutical industry — coupled with a changing future environment — the current commercial model is too cumbersome to deal with hard economic conditions or to react to new stakeholder environmentsmore

Pfizer and BI get expanded label for Spiriva for COPD – Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). SPIRIVA HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with COPD, which includes chronic bronchitis, emphysema, or bothmore

Cancer genomes revealed – this is pretty cool, actually. A big step toward personalized medicine.

Medical Rep certification – coming soon!

RECOMMENDED

Training and eMarketing. The Impactiviti network has great suppliers for all your training, social media, and eMarketing needs.  We “matchmake” best-in-class vendor/providers with clients’ needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

JUST FOR FUN

Business Week gives their visual and descriptive accounting of the 50 ugliest cars of the last 50 years. There are some…umm…beauties in there.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Welcome back from Thanksgiving holiday! Can’t believe it’s already December…

This will be the only Impactiviti Daily this week, as I am heading down to South Carolina for the graduation of my #2 son (David) from Marine boot camp.

TODAY’S NEWS

Layoffs. Sanofi reps are apparently getting the news this week. Ugh.

Will Celgene‘s Revlimid take off even faster? – Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Johnson & Johnson’s intravenous medicine, Velcade.

Court to Glaxo reps seeking overtime pay: No. FDA to Novartis on seasonal flu shot: Yes.

RECOMMENDED

Speaker Training. The Impactiviti network of providers has what you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Mystic the Marketing Lab gives her first interview. On canine branding.

JUST FOR FUN

Twenty amazing photographers from around the Internet.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Whew! The back-to-back conference marathon is now over, and we can get back to our regular pharma news reporting. Here’s what’s up today…

TODAY’S NEWS

Everyone’s talking about the Zetia/Niaspan study – its results, its significance, its limitations. Bottom line – I can’t see how this can be good for Merck. More here. And Jim Edwards analyzes the damage control spin effort here.

Always a headline topic: female sexual desire treatments. The more you read about this drug (experimental ‘flibanserin’ from Boehringer-Ingelheim), however, the more you wonder if the purported effect will be worth the expense and the side effects.

BMS pushing Mead-Johnson out of the nest. It is amazing to me how drug companies cycle through periods where they diversify, then spin divisions off…

Novartis: half a dose of H1N1 vaccine may be enough. Now that’s how to increase vaccine supply!

If you’re going to blow the whistle, I guess it’s important to get on to the field of play! Whistleblower lawsuit against J&J dismissed.

RECOMMENDED

Leadership – talent selection. How is your organization choosing leaders? Impactiviti’s provider network has proven, best-in-class talent selection/management solutions. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Is this drug a frog, or a prince? I dunno, but I like the picture…!

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

« Newer Posts - Older Posts »